Skip to main content
. Author manuscript; available in PMC: 2014 Oct 2.
Published in final edited form as: J Immunol. 2012 May 21;188(12):6407–6417. doi: 10.4049/jimmunol.1102492

Table I.

CS14K priming induces sterile protection

Priminga Boostingb Challengec Protected/Challenged
(% Protected)
Prepatent
Period
CS14K MVA-CS 300 sporozoites 10/10 (100) __
PBS PBS 14 d after boost 0/10 (0) 4d
a

Protein (20µg) administered intradermally.

b

Virus (2×107 PFU) administered i.p.

c

Challenge via i.v. route.